Table.Briefings

Feature

epa07592272 People work in Hengrui Medicine research laboratory in Lianyungang, Jiangsu Province, China, 21 May 2019.
Town of Lianyungang hosts two large scale but essentially different medical and pharmaceutics companies. 
Differences between Western medicine and Traditional Chinese medicine (TCM) are various such as approaches to the patient exams and medical prescriptions.  The Western approach clearly divides the health from the disease, yet TCM approach considers health as a balanced state vs disease as an unbalanced state.
Hengrui Medicine company specializes in anti-tumor research and it is the largest producer of cancer related drugs in China. It was 64th on Forbes 2018 list of world's most innovative companies. Companies most famous drug is Docetaxel witch can be used for prostate and adaptive breast cancer, and it's approved by FDA of US. Another medicine is called Cyclophosphamide with great effects on lymphoma leukemia and multiple melanoma. Company clams this drug take about half of the US market share.
Kanion Pharmaceutical is has the largest intelligent line of traditional Chinese herbal medicine extraction in China. Company has the largest number of innovation patents in Chinese medicine industry. TCM or Traditional Chinese Medicine is one of the oldest healing systems on the planet. Includes herbal medicine, dietary therapy, acupuncture, massage and exercise.  It stimulates the body's own healing mechanism and takes into account all aspects of patient's life, rather then just several obvious signs of symptoms.
EPA-EFE/ALEKSANDAR PLAVEVSKI  EPA-EFE/Aleksandar Plavevski

Dependence also for ibuprofen and paracetamol

Many pharmaceuticals and their active ingredients, like ibuprofen or paracetamol, nowadays come from China or India. This makes Germany dependent in this area as well – and is a problem if supply chains become disrupted.

By Redaktion Table

COP15: dispute over financing and the private sector's role

Financing the biodiversity targets is the Achilles' heel of the UN Biodiversity Conference (COP15). In addition to mobilizing public funds, this involves nothing less than aligning the entire economy with "nature positive." Support comes from the private sector itself.

By Timo Landenberger

COP15: natural climate protection under pressure

The COP15 biodiversity conference now enters its decisive phase. So far, however, little progress has been made. And now the protection of natural areas, which are key to carbon uptake and climate action, is also on the line.

By Timo Landenberger

Planned LNG terminals in Germany

German ministry predicts overcapacity at LNG terminals

In an internal report, the Ministry for Economic Affairs admits that the LNG terminals planned in Germany will lead to overcapacity. The budget committee has already blocked the funds for one of the terminals, and the ministry no longer believes in the planned terminal in Hamburg.

By Malte Kreutzfeldt

How the UK lost its climate compass

The UK is not on track to meet its climate targets and its ability to do so is looking increasingly compromised in the face of the government’s Jekyll and Hyde approach to climate and energy policy. This month it has both approved the first deep coal mine in the UK for 30 years and agreed to ease the ban on onshore wind turbines.

By Redaktion Table

EP affair: quid pro quo?

The European Parliament is trying to find out where ex-Vice President Eva Kaili, who has been accused of corruption, may have exerted undue influence. The aviation agreement with Qatar and lobbying activities in the IT sector are the focus.

By Markus Grabitz

EU ignores China's failings in Eastern and Central Europe

China raised high expectations in Central and Eastern Europe with 16+1 talks. But what followed was great disillusionment. Ten years after its founding, the format is on the verge of collapse. It is up to the EU to use this opportunity, but so far it has failed to do so.

By Michael Radunski